Physician profile
Patrick O Mcmanamon
NPI 1780114603
$4,098.90
in general payments reported to CMS, 2019-2025
23 companies · $597 in 2025
The $597 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $262 · 2021: $583 · 2022: $713 · 2023: $415 · 2024: $1,073 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,735 · Consulting Fee: $300 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,735.29 |
| Consulting Fee | $300.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,033.77 | 2019-2025 | Clareon, Hydrus Microstent, Air Optix |
| Glaukos Corporation | $543.37 | 2023-2025 | Ce-Marked Kxla System, Idose, Idosetr |
| Johnson & Johnson Vision Care, INC. | $371.54 | 2019-2024 | Acuvue |
| Coopervision INC. | $359.35 | 2019-2024 | Clariti Contact Lens |
| Oyster Point Pharma, INC. | $310.98 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $281.61 | 2024-2025 | Xdemvy |
| Rxsight INC | $262.16 | 2023-2024 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Aerie Pharmaceuticals, INC. | $212.35 | 2019-2021 | |
| Dompe US, INC. | $145.36 | 2020-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $123.72 | 2022-2025 | Miebo, Xiidra, Alden Scleral Zenlens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $117.01 | 2019-2021 | |
| Biotissue Holdings INC. | $73.28 | 2024 | |
| Sun Pharmaceutical Industries INC. | $43.55 | 2021-2022 | |
| Eyevance Pharmaceuticals LLC | $35.80 | 2022-2023 | Flarex |
| Quidel Corporation | $27.86 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $27.02 | 2023 | Rayone Aspheric, Rayone Emv, Rayone Spheric |
| Harrow Eye, LLC | $23.82 | 2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $21.36 | 2019 | |
| Sight Sciences, INC. | $20.24 | 2022 | |
| Abbvie INC. | $17.92 | 2024 | |
| Spark Therapeutics, INC. | $17.18 | 2019 | |
| Ani Pharmaceuticals, INC. | $16.17 | 2024 | Purified Cortrophin Gel |
| Beaver-Visitec International, INC. | $13.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Mcmanamon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.